Clinical trials: Pulmonary Hypertension
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension
Imatinib (QTI571) in Pulmonary Arterial Hypertension
A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).
- Trial name
- IMPRES (NCT00902174)
- Testing
- imatinib mesylate
- Where
- 95 sites in United States, Austria and 12 more
- Volunteers
- 202 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
This is a multicenter, single-arm trial to evaluate the safety of the transition from Selexipag to Remodulin® then Oral Treprostinil in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT03016468
- Testing
- Parenteral Remodulin (treprostinil) injection, Oral Treprostinil
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
This study is designed to understand the relative bioavailability (proportion of the administered dose that is absorbed into the bloodstream) of several fixed dose combinations (FDCs) tablets of ambrisentan and tadalafil for…
- Trial name
- NCT02688387
- Testing
- FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Hypertension
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
- Trial name
- NCT00091715
- Testing
- bosentan
- Where
- 34 sites in United States, Australia and 12 more
- Volunteers
- 185 people
- Sponsor
- Actelion
Pulmonary Hypertension
REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
The REVEAL Registry™ is a multicenter, observational, U.S.-based study of the clinical course and disease management of pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT00370214
- Where
- 54 sites in United States
- Volunteers
- 3,515 people
- Sponsor
- Actelion
Pulmonary Hypertension
The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting
A Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15 "Power 15 Study"
- Trial name
- NCT00467896
- Testing
- Iloprost PD-6, Iloprost PD-15
- Where
- 12 sites in United States
- Volunteers
- 62 people
- Sponsor
- Actelion
Primary Pulmonary Hypertension
Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety and tolerability of LIQ861, a dry powder formulation of treprostinil, in patients with Pulmonary Arterial Hypertension (PAH).
- Trial name
- INSPIRE (NCT03399604)
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 38 sites in United States
- Volunteers
- 121 people
- Sponsor
- Liquidia Technologies, Inc.
Primary Pulmonary Hypertension
Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil
The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).
- Trial name
- NCT03992755
- Testing
- LIQ861 Inhaled Treprostinil
- Where
- 25 sites in United States
- Volunteers
- 92 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension
Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of JTT-251 administered for 24 weeks in participants with pulmonary arterial hypertension (PAH)
- Trial name
- RELIEF-PAH (NCT03789643)
- Testing
- JTT-251
- Sponsor
- Shionogi Inc.
COPD, Pulmonary Hypertension
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the…
- Conditions
- COPD, Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Trial name
- NCT03135860
- Testing
- Inhaled Nitric Oxide 30mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Bellerophon
Pulmonary Arterial Hypertension
Implantable System for Remodulin Post-Approval Study
The purpose of the Implantable System for Remodulin (ISR) Post Approval Study (PAS) is to provide evaluation and periodic reporting of the safety and effectiveness of Medtronic market-released ISR, including the catheter and the…
- Trial name
- ISR PAS (NCT03833323)
- Testing
- Implantable System for Remodulin (treprostinil)
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Hypertension, Pulmonary
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)
The primary purpose of this study is to identify and develop biomarker signatures based on circulating micro ribonucleic acid (RNA) in the blood samples associated with high risk of pulmonary hypertension (PH) to assist in the…
- Trial name
- CIPHER (NCT04193046)
- Testing
- Blood Sample
- Where
- 49 sites in United States, Belgium and 7 more
- Volunteers
- 907 people
- Sponsor
- Janssen Research & Development, LLC
Persistent Fetal Circulation Syndrome
Sildenofil in Persistent Pulmonary Hypertension in Newborns
This study hopes to evaluate the effectiveness of early combined use of Sildenafil and nitric oxide (iNO) in newborns with Persistent pulmonary hypertension (PPHN) and or hypoxemic respiratory failure and assess whether this…
- Trial name
- Sildeno (NCT01558466)
- Testing
- Sildenafil, diluent
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Pulmonary Hypertension
FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- NCT00760916
- Testing
- UT-15C 1 mg, UT-15C 0.25 mg, UT-15C 5 mg
- Where
- 31 sites in United States, Australia and 1 more
- Sponsor
- United Therapeutics
Hypertension,Pulmonary
Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension
The SAPPHIRE clinical trial seeks to establish the efficacy and safety of repeated monthly dosing of autologous EPCs transfected with human eNOS (heNOS) in patients with symptomatic severe PAH on available PAH-targeted medical…
- Trial name
- SAPPHIRE (NCT03001414)
- Testing
- Autologous EPCs transfected with human eNOS
- Where
- 4 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Northern Therapeutics
Pulmonary Arterial Hypertension
Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)
This clinical trial will study the safety, tolerability, and pharmacodynamics of single doses of MK-8892 in participants with pulmonary arterial hypertension (PAH).
- Trial name
- NCT01934647
- Testing
- MK-8892
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary…
- Trial name
- NCT06603285
- Testing
- Treprostinil
- Volunteers
- 20 people
- Sponsor
- Excelsior
Chronic Thromboembolic Pulmonary Hypertension
Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension
Long-term study to evaluate if macitentan is safe, tolerable and efficient enough to be used for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
- Trial name
- MERIT-2 (NCT02060721)
- Testing
- Macitentan
- Where
- 33 sites in Belgium, China and 13 more
- Volunteers
- 76 people
- Sponsor
- Actelion